In an effort to improve the outcome of poor-risk lymphoma patients, we evaluated a novel regimen of tandem high-dose chemotherapy (THDC) with autologous stem cell transplantation. A total of 41 patients (median age 40 years, range 15-68 years) with poor-risk nonHodgkin's lymphoma and Hodgkin's disease were enrolled. THDC consisted of melphalan (180 ), (ETCb) as the second regimen. In all, 31 patients (76%) completed both transplants, with a median time between transplants of 55 days (range 26-120). The maximum tolerated dose was determined as 40 mg/m 2 for mitoxantrone and 550 mg/m 2 for etoposide phosphate. The overall toxic death rate was 12%. Following high-dose chemotherapy, 10 of 24 evaluable patients (42%) were in CR. The two-year overall survival and event-free survival is 67% (95% CI, 52-81%) and 45%, (95% CI, 29-61%) for the 41 patients enrolled; and 69% (95% CI, 525-586%) and 48% (95% CI, 30-67%) for the 31 patients completing both transplants. This THDC regimen is feasible but with notable toxicity in heavily pretreated patients; its role in the current treatment of high-risk lymphoma remains to be determined.
phoma
The majority of poor-risk lymphoma patients are not cured with conventional chemotherapy. High-dose chemotherapy (HDC) with peripheral blood progenitor cell support (PBPC) offers a survival advantage in such patients, but many still die from recurrent disease. 1 Strategies to improve survival in patients with poor risk, relapsed, or chemotherapy-resistant disease include intensified induction followed by HDC with PBPC support, [2] [3] [4] [5] HDC with autografting and immunotherapy, 6 tandem HDC and autografting, [7] [8] [9] [10] [11] [12] or sequential autologous and nonmyeloablative allogeneic transplantation. Tandem transplantation as a strategy to improve efficacy was demonstrated in myeloma by Barlogie et al 13 and Attal et al. 14 In an attempt to improve outcome in patients with high-risk lymphoma, our group examined the tolerability and efficacy of two regimens, first, mitoxantrone and melphalan (MMt) and second, etoposide, thiotepa, and carboplatin (ETCb), given in sequence with PBPC support in a program of tandem autologous transplantation. As first-line therapy for newly diagnosed poor-risk lymphoma, Corradini et al 15 reported favorable results using myeloablative doses of melphalan and mitoxantrone followed by autografting. Based on this report, we studied the utility and determined the maximum tolerated dose (MTD) of MMt given before the first transplant performed in our tandem autografting protocol for patients with poor-risk, resistant or relapsed disease.
For our second autograft procedure, we devised a myeloablative conditioning regimen of ETCb. This combination derived from our experience with the high-dose combinations of cyclophosphamide, thiotepa, and carboplatin that we and others have used for breast cancer, and carmustine, thiotepa, and etoposide that we have reported for brain tumors. 16, 17 We sought to determine the MTD of etoposide phosphate in combination with thiotepa and carboplatin in the ETCb regimen. Etoposide phosphate offered the advantages of requiring less hydration and an abbreviated time of administration relative to conventional etoposide. 18 We report our single institution experience in treating 41 lymphoma patients and establish the MTD of this novel tandem HDC regimen of MMt and ETCb with autologous PBPC support.
Patients and methods

Patients
A total of 41 eligible patients with poor-risk, resistant or relapsed non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) were enrolled in this study between May 1997 and June 2003. Patient enrollment was hampered by thirdparty insurance denials. Eligibility criteria included ECOG performance status 0-1, HIV seronegative, left ventricular ejection fraction 444%, diffusion capacity for carbon monoxide (DLCO) 459%, adequate renal and hepatic function, and adequate CD34 þ cells. The protocol was approved by our Institutional Review Board. Written informed consent was obtained.
PBPC collection and re-infusion
PBPC were mobilized with chemotherapy followed by GM-CSF. Regimens for mobilization were determined according to clinical circumstances. GM-CSF was commenced 24 h after chemotherapy at 500 mg daily and continued until completion of PBPC collection. The criterion for adequate PBPC collection required a total CD34 þ count of 42 Â 10 6 cells/kg. Harvested cells were processed, suspended in a 5% DMSO, 4% albumin and 6% hydroxyethyl starch cryopreservation solution and stored at À801C. Prior to reinfusion, harvested cells were thawed and volume-reduced where necessary as previously described. 17 
High-dose chemotherapy
The first high-dose regimen of MMt therapy consisted of melphalan and escalating doses of mitoxantrone. The dose of mitoxantrone was increased from 30 mg/m 2 in increments of 10 mg/m 2 until the MTD was determined. Mitoxantrone was infused over 1 h in three divided doses every 2 h on day À4. Melphalan 90 mg/m 2 /day was given over 30 min on day À2 and day À1.
Patients proceeded to ETCb therapy when they achieved an absolute neutrophil count (ANC) 41 Â 10 /day given as 5 h infusions on days À7 to À4. The median calculated carboplatin AUC covering the total 800 mg/m 2 dose was 9.5 min mg/ml (range 7.4-13.8 min mg/ml). When the MTD of mitoxantrone was determined, dose escalation of etoposide was commenced in increments of 150 mg/m 2 from an initial total dose of 400 mg/m 2 .
Definitions
Dose limiting toxicity (DLT) was defined as life-threatening (grade IV) or lethal (grade V) organ damage. For both mitoxantrone and etoposide, if DLT occurred in two of three patients, then the prior dose was designated the MTD. If only one of the first three patients had DLT, then up to 3 additional patients were treated at that dose. A minimum of three weeks must have elapsed after treatment of the last patient at the prior dose level before enrollment of patients on the next dose level. Toxic death was death from any cause occurring within 100 days of ASCT.
All patients received GM-CSF 500 mg/day beginning on the day of PBPC infusion (day 0) until the white blood cell count (WBC) reached 45 Â 10 9 /l. Engraftment was defined as the first of 2 consecutive days on which the patient's ANC was 40.5 Â 10 9 /l following the nadir and the first of 3 consecutive days on which the patient's unsupported platelet count was 420 Â 10 9 /l. Platelets were transfused for a platelet count o20 Â 10 9 /l or for active bleeding. Response criteria were standard for lymphoma. Patients in complete response (CR) prior to HDC who remained in CR were classified as continued CR (cCR). Patients were assessed by CAT prior to commencing HDC and at 8-12 weeks following ETCb. Follow-up staging was performed approximately every 3 months or earlier if clinically indicated.
Primary graft failure was defined as continued WBC below 3 Â 10 9 /l and continual requirement for blood and/or platelet transfusion 3 months after ASCT. Secondary graft failure was defined as a cytopenia (WBC o3 Â 10 9 /l, platelets o100 Â 10 9 /l) occurring after full initial engraftment and unrelated to therapy or disease progression.
Statistical analysis
Descriptive statistics are reported as medians. Overall survival (OS) was defined from time of first HDC regimen to time of death or last follow-up. Event-free survival (EFS) was determined from time of first HDC regimen to time of disease progression, relapse, second malignancy, death from any cause or last follow-up. Curves were estimated by the Kaplan-Meier product limit method. Data were analyzed in Statview release 5.01 (SAS Institute Inc., Cary, NC, USA).
Results
Patients
Of the patients with NHL, 12 (44%) had diffuse large B-cell lymphoma (Table 1) . There were nine patients with T-cell lymphoma and 13 with HD. Seven patients considered at high-risk for relapse, including four patients with T-cell lymphomas, were in first CR at the time of tandem transplant. In all, 17 patients (six HD, 11 NHL) had failed to achieve a CR and 17 (seven HD, 10 NHL) had relapsed less than 1 year following CR with conventional chemotherapy. Of the patients, 83% had stage III or IV lymphoma at initial diagnosis and 76% had received X2 chemotherapeutic regimens prior to enrollment.
Peripheral blood progenitor cell collection and infusion
The median number of days of leukopheresis was 3 (range 1-11) to collect a median of 8.9 (range 4.4-37.8) Â 10 6 CD34 þ cells/kg. The median number of CD34 þ cells infused was 3.7 (range 2.2-10.5) Â 10 6 CD34 þ cells/kg after MMt and 4.3 Â 10 6 CD34 þ cells/kg (range 1.7-17.1) after ETCb (Table 2) .
Hematological recovery, blood product utilization and hospital stay Hematological parameters for each HDC are summarized in Table 2 . In patients achieving engraftment following MMt, the median time to ANC 40.5 Â 10 For patients proceeding to the second autograft, the median interval to initiation of ETCb was 55 days (range 26-120). Following ETCb and the second transplant, the median time to ANC 40.5 Â 10 9 /l was 11 days (range [9] [10] [11] [12] [13] [14] and median time to platelet count 420 Â 10 9 /l was 12 days (range 8-72). Three patients who died of sepsis remained platelet-dependent. Blood product utilization included a median of 4 units (range 0-16) of packed red cells and 4 units (range 2-26) of platelets. The median number of days of hospitalization was 22 days (range 18-61).
MMt high-dose chemotherapy
A total of 41 patients received MMt. Following episodes of severe mucositis (grades III/IV) and life-threatening sepsis in two of five patients receiving mitoxantrone 50 mg/m 2 , the MTD was determined as 40 mg/m 2 ; a total of 33 patients were treated at this dose level.
Nonhematological toxicities (grade III-V) are summarized in Table 3 . Mucositis requiring intravenous or transdermal analgesia occurred in most patients (59%). Seven patients (17%) required parenteral nutrition. Thirty patients experienced neutropenic fever and received intravenous antibiotics. Pathogens were documented in 14 of these patients, including Staphylococcus epidermidis, four, S. hemolyticus, four, Escherichia coli, two, and vancomycin-resistant Enterococcus fecalis, S. hominis, S. salivarius, and Klebsiella species, one each. Septic shock requiring pressor support occurred in four patients, one of whom died.
Following mitoxantrone 40 mg/m 2 , five patients developed cardiac failure, one patient with a persistent sinus tachycardia. Of these five, three NHL patients developing heart failure received prior doses of doxorubicin at 510, 561, and 581 mg, respectively. One NHL patient received prior doxorubicin (330 mg) and mitoxantrone (13.5 mg) and a HD patient received doxorubicin (1036 mg) and 36 Gy mediastinal radiation therapy. All patients responded to medical antifailure therapy. Two patients had transient hyperbilirubinemia but no other evidence for veno-occlusive disease. Grade III diarrhea occurred in two patients, one of whom had Clostridium difficile infection.
ETCb high-dose chemotherapy
In all, 10 (24.4%). of the original 41 patients did not proceed to ETCb conditioning and the second transplant: two patients suffered toxic deaths (including one patient with rapid disease progression), two patients had clinical disease progression, and six chose not to undergo the second procedure.
A total of 31 patients proceeded to ETCb and the second autograft. As a result of three toxic deaths due to sepsis among six patients who received 4700 mg/m 2 of etoposide phosphate, the MTD of etoposide was determined as 550 mg/m 2 . A total of 13 patients were treated at this dose level; all 13 had received the MTD of mitoxantrone (40 mg/m 2 ) in the MMt regimen. Mucositis occurred in 39% of patients, three of whom required parenteral nutrition. A total of 24 patients experienced neutropenic fever and received intravenous antibiotics. Pathogens were documented in 11 of these patients, including S. epidermidis in three episodes, Enterobacter cloacae, two, and S. hemolyticus, Streptococcus mitus, vancomycin-resistant enterococcus, E. coli, Klebsiella pneumoniae, Candida albicans, and C. glabrata, one each. Three patients died from infectionrelated complications, including disseminated tuberculosis secondary to Mycobacterium tubercuolosis endocarditis in one case, disseminated C. fungemia, one, and both Enterobacter sepsis and Hafnia alvei infection, one. Herpes infection occurred in two patients during their period of neutropenia. Grade III/IV diarrhea was noted in 10 patients, three of whom had evidence of Clostridium difficile infection. Three patients experienced hepatic toxicity, one of whom had transient veno-occlusive disease.
Response and outcome
Of the eight assessable patients who did not proceed to ETCb, two were in cCR, two patients attained CR, two had stable disease (SD), and two had disease progression (PD) following MMt. There were two toxic deaths following MMt.
Of 31 patients receiving both MMt and ETCb with PBPC support, four remained in cCR, 10 patients attained CR, seven patients had SD, and seven patients had PD. There were three toxic deaths following ETCb. In 34 patients with evaluable disease, the overall intention to treat response was 35% (12 responding patients). Of 24 evaluable patients receiving both MMt and ETCb, 10 (42%) showed a response.
The 2-year overall survival and event-free survival was 67% (95% CI, 52-81%) and 45%, (95% CI, 29-61%) Figure 1) ; and 69% (95% CI, 52-86%) and 48% (95% CI, 30-67%), respectively, for the 31 patients completing both transplants. There was no significant difference in EFS or OS between the NHL and HD patients with evaluable disease. Of the 41 patients, five (12%) suffered a toxic death.
At the time of analysis, with a median follow-up of 44 months (range 6-78 months), 19 patients (46%) remain alive, including one patient treated for early stage lung cancer. Five patients in CR before HDC remain in CR. Four patients were lost to follow-up. Following PD, patients who were suitable candidates were further therapy were treated as per their physician's choice. In all, 11 patients (27%) have died from disease progression, one patient developed myelodysplastic syndrome and died while undergoing nonmyeloablative allogeneic transplantation, and one patient died from esophageal cancer.
Discussion
We report on a pilot study of tandem autologous transplantation in which mitoxantrone (30-50 mg/m In the process of determining MTD, we noted five toxic deaths, three following ETCb in patients who received X700 mg/m 2 of etoposide. Tandem transplantation using our two conditioning regimens at the determined MTD was feasible in the majority of our poor-risk, heavily pretreated patients. As a result of the study design and patient heterogeneity, overall efficacy cannot be compared to the results of previous studies of single HDC and autografting in lymphoma. Nevertheless, CR was noted in 10 (42%) of the 24 evaluable patients with measurable disease completing both transplants. Four of 12 patients with measurable disease (30%) treated with MMt and ETCb at the MTD had complete response. The 2-year overall survival and time to progression were 69 and 48%, respectively, for the 31 patients receiving both transplants.
Four studies of tandem HDC with autologous PBSC support as salvage therapy have utilized regimens containing BCNU, cyclophosphamide, mitoxantrone, busulfan and radiation therapy. 7, 8, 10, 11 In a patient population comparable to ours, Fitoussi et al 7 ) with TBI (12 Gy) or busulfan (8-12 mg/kg). At day 100 following cycle 2, there were two treatment-related deaths due to hepatic VOD, with a 67% CR rate. Despite these toxicities, median survival was 19 months with an encouraging 2-year survival rate of 80%.
A multicenter phase II trial (PARMA2) tested the efficacy of tandem autologous HDC in NHL patients relapsing within the first year of diagnosis. 8 Patients underwent the first cycle of BEAC with PBPC support, and if in CR or PR, received carboplatin (1200 mg/m 2 ), melphalan (140 mg/m 2 ), and TBI (12 Gy) or busulfan as the second HDC regimen. Of 16 patients enrolled, 14 proceeded to the first HDC cycle with BEAC. Nine patients had both HDC regimens. There were three toxic deaths following the second HDC. Of the remaining six patients, three were in CR and three were in PR. At a median followup of 9 months, the median survival was 5 months. Owing to the perceived poor results and high toxic death rate this study was halted.
Brice et al 10 , and TBI (12 Gy) or busulfan (12-16 mg/kg). Despite a median age of 29 years, only 74% of enrolled patients completed both cycles. There was one toxic death and two patients developed VOD. On an intention to treat analysis, the CR rate was 51%. For the 43 enrolled patients and the 32 patients completing the tandem transplant, the 2-year survival were 65 and 74%, respectively.
Ballestrero et al 9 reported on a similar MMt regimen as part of a tandem HDC protocol in the initial treatment of 25 patients with aggressive NHL. Their tandem HDC regimen differed from ours in dose and omitted thiotepa in the second HDC regimen. In their study, patients were given mitoxantrone (60, 75, or 90 mg/m following MMt, they found no acute cardiac toxicities during early recovery from autografting. In contrast, 12% of our patients suffered cardiotoxicity following MMt; our higher incidence of cardiac events may possibly be related to greater prior exposure to anthracyclines and radiation in our heavily pretreated patients. Mucositis and neutropenic fever with infection resulted in significant morbidity and mortality in our study. Opportunistic infections have been frequently noted following tandem autologous transplantation. 12 These infections are likely to be due to a combination of factors, including the underlying disease and the intensity of chemotherapy affecting lymphocyte and stromal function.
The tandem transplantation regimen of MMt and ETCb at the MTD established in our study can be administered and for the most part is tolerable, considering the patient population enrolled. A number of our patients failed to respond or progressed after tandem HDC. When one considers the increased toxicity, it is not clear that the possible benefit of this strategy can balance the effect on quality of life and potential for medium to long-term toxicity. The CR rate for poor-risk and relapsed patients undergoing tandem therapy may be improved, but a clear demonstration of clinical benefit with acceptable long-term toxicity is necessary before tandem transplantation becomes a viable therapeutic choice over the current approaches to poor-risk patients. 20 Although not tested in a randomized fashion, when used as consolidative therapy in responding poor-risk patients, Haioun et al 12 concluded that tandem transplant did not improve on the results of patients receiving a single consolidative HDC regimen. HDC regimens that include newer targeted therapeutic modalities such as rituximab offer the possibility of improved efficacy and decreased toxicity. 21, 22 The results of randomized trials of HDC with immunotherapy are awaited with interest.
